ACE.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$6M	-81.7%	$-0.27	$-2.43–$0.81	—	3
2027	$15M	+146.7%	$-0.07	$-0.16–$0.11	—	3
2028	$29M	+92.7%	$-0.07	$-0.07–$-0.07	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-20	$0.50	$-0.13	-126.0%
2026-02-05	$0.50	$-0.13	-126.0%
2025-11-05	$-0.10	$-0.13	-30.0%
2025-08-18	$-0.10	$-0.10	+0.0%
2025-05-19	$-0.20	$-0.20	+0.0%
2025-02-07	$-0.20	$-0.14	+30.8%
2024-11-07	$-0.20	$-0.42	-110.0%
2024-08-15	$-0.28	$-0.39	-39.3%

DCF fair valuemodel estimate

Intrinsic value

$0.44

Price

$0.60

Implied downside

-26%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ACE.STAscelia Pharma AB (publ)	$0.61	-1.93%	$81M	—
ELIC.STElicera Therapeutics AB (publ)	$2.91	-2.18%	$194M	—
IMMU.STMendus AB (publ)	$6.22	-6.33%	$381M	—
IRLAB-A.STIRLAB Therapeutics AB (publ)	$1.84	+0.33%	$269M	—
ISOFOL.STIsofol Medical AB (publ)	$0.72

Ascelia Pharma AB (publ)

Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.

www.ascelia.com

Employees: 10
IPO / List date: Mar 13, 2019
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds ACE.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ACE.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ACE.ST yet.